Introduction
Invasive fungal infections are an important cause of morbidity and mortality in children. Triazole antifungal agents are increasingly used for prophylaxis and treatment of mould infections in paediatric oncology settings, however, confer a risk of azole-induced hepatotoxicity (AIH), particularly when concomitantly administered with other hepatotoxic medications. There are limited data on the best approach to AIH. As triazole antifungal agents are the only antifungal formulation available in oral form for children, one described approach is switching between different triazole agents within the azole class to prevent the need for intravenous (IV) therapy. To date, there have only been three case reports and one retrospective audit in adults of this approach1-4. This study therefore aimed to describe the outcomes of switching triazole antifungal agents for AIH in children.